Telaprevir

Summary

Telaprevir (brand names Incivek, Incivo) is an oral, prescription peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3/4A protease. Approved in 2011 for genotype 1 infection, it was used together with pegylated interferon and ribavirin to raise cure rates. By 2013 it was withdrawn from the market as newer, more effective, interferon‑free regimens replaced it.

Mechanism of Action

Telaprevir binds to the active site of the HCV NS3/4A serine protease, a viral enzyme required for cleaving the viral polyprotein into functional components. By blocking this proteolytic step, the drug halts the formation of mature viral proteins, preventing replication of the hepatitis C virus within infected hepatocytes.

What the Research Shows

Clinical trials reported that adding telaprevir to peginterferon‑alpha and ribavirin increased sustained virologic response rates for genotype 1 patients from roughly 45% to about 70%, shortening treatment duration to 12 weeks of telaprevir. However, dermatologic toxicity was common; a pooled analysis showed skin eruptions in 56% of telaprevir recipients versus 34% with standard therapy, with severe reactions (3.7% vs 0.4%) including Stevens‑Johnson syndrome and DRESS. Pharmacovigilance updates highlighted severe mucocutaneous reactions when combined with rituximab. By 2013, second‑generation direct‑acting antivirals offering >90% cure without interferon rendered telaprevir obsolete, leading to its market withdrawal.

Reported Benefits

When combined with peginterferon and ribavirin, telaprevir provided a notable improvement in cure rates for HCV genotype 1, raising sustained virologic response to around 70% and allowing a shorter interferon‑containing regimen. This represented a therapeutic advance over interferon‑ribavirin alone at the time of its approval.

Limitations of the Evidence

Telaprevir required co‑administration with interferon and ribavirin, both of which have substantial side‑effects, limiting tolerability. High incidence of skin reactions, including rare but serious SJS and DRESS, posed safety concerns. Its efficacy was restricted to genotype 1, and resistance mutations emerged. Newer DAAs demonstrated >90% cure rates without interferon, leading to telaprevir’s withdrawal.

Safety Considerations

Dermatologic adverse events were the most prominent safety issue: over half of treated patients developed pruritic eczematous dermatitis, and severe cutaneous reactions occurred in a minority (≈3.7%). Reports of Stevens‑Johnson syndrome and DRESS prompted heightened monitoring. Pharmacovigilance also noted severe mucocutaneous reactions when telaprevir was used with rituximab. Caution is advised for patients with a history of severe skin disorders.

How It Is Administered

Telaprevir was administered orally as tablets, typically taken three times daily for a 12‑week period in combination with pegylated interferon‑alpha and ribavirin. The regimen required close clinical monitoring for dermatologic toxicity and drug‑drug interactions.

Routes of Administration

Goals & Uses

• Sustained virologic response (SVR)Clinical EndpointHigh
• Chronic HCV genotype 1 treatmentAntiviral TherapyHigh
• Treatment-experienced HCV patientsAntiviral TherapyHigh

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Concomitant use of strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort)Drug InteractionHigh
• Hypersensitivity to telaprevir or excipientsAllergyHigh
• Concomitant use of drugs highly dependent on CYP3A4 with narrow therapeutic index (e.g., alfuzosin, ergot derivatives, cisapride, pimozide, simvastatin, lovastatin)Drug InteractionHigh

Adverse Effects

• HyperuricemiaMetabolicUncommon
• AnemiaHematologicCommonLow red blood cell count or hemoglobin
• Rash (including DRESS and Stevens-Johnson syndrome)DermatologicCommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Anorectal discomfort/pruritus aniGastrointestinalCommon
• FatigueGeneralCommonLow energy or tiredness

Drug Interactions

• RifampinHigh
• Simvastatin / LovastatinHigh
• Tacrolimus / CyclosporineHigh
• Midazolam (oral)High
• Hormonal contraceptivesModerate
• Amiodarone / AntiarrhythmicsModerate

Population Constraints

• PregnancyReproductive SafetyAbsolute
• Pediatric patients (<18 years)AgeAbsolute
• Hepatic decompensation (Child-Pugh B/C)Hepatic ImpairmentAbsolute
• HIV/HCV co-infection with antiretroviralsDrug InteractionRelative
• HCV non-genotype 1 infectionIndicationAbsolute

Regulatory Status

• European UnionWithdrawnApproved: Chronic hepatitis C genotype 1 in adults in combination with peginterferon alfa and ribavirinEMA approval granted 2011; marketing authorization withdrawn at request of marketing authorisation holder in 2014.
• United StatesWithdrawnApproved: Chronic hepatitis C genotype 1 in adults in combination with peginterferon alfa and ribavirinFDA approved May 23, 2011; voluntarily withdrawn by Vertex Pharmaceuticals in October 2014 due to availability of superior therapies.
• United KingdomWithdrawnApproved: Chronic hepatitis C genotype 1 in adults in combination with peginterferon alfa and ribavirinFollowed EMA withdrawal; no longer available in the UK market.

FDA approved May 2011; withdrawn from US market October 2014. EMA approved 2011; withdrawn from EU market 2014. Manufacturer (Vertex Pharmaceuticals) voluntarily withdrew the product globally.

Evidence & Sources

• [Pharmacovigilance update]
  Journal ArticleModerateDiezi L, et al.2014-01-01T00:00:00.000000Z
• Direct anti-HCV agents
  Journal ArticleModerateZhang X2016-01-01T00:00:00.000000Z
• Telaprevir-related dermatitis
  Journal ArticleModerateRoujeau JC, et al.2013-01-01T00:00:00.000000Z

Frequently Asked Questions